-
Arsenal's Merino has earned striking role: Arteta
-
Putin offers India 'uninterrupted' oil in summit talks with Modi
-
New Trump strategy vows shift from global role to regional
-
World Athletics ditches long jump take-off zone reform
-
French town offers 1,000-euro birth bonuses to save local clinic
-
After wins abroad, Syria leader must gain trust at home
-
Slot spots 'positive' signs at struggling Liverpool
-
Eyes of football world on 2026 World Cup draw with Trump centre stage
-
South Africa rugby coach Erasmus extends contract until 2031
-
Ex-Manchester Utd star Lingard announces South Korea exit
-
Australia edge ominously within 106 runs of England in second Ashes Test
-
Markets rise ahead of US data, expected Fed rate cut
-
McIlroy survives as Min Woo Lee surges into Australian Open hunt
-
German factory orders rise more than expected
-
India's Modi and Russia's Putin talk defence, trade and Ukraine
-
Flooding kills two as Vietnam hit by dozens of landslides
-
Italy to open Europe's first marine sanctuary for dolphins
-
Hong Kong university suspends student union after calls for fire justice
-
Asian markets rise ahead of US data, expected Fed rate cut
-
Nigerian nightlife finds a new extravagance: cabaret
-
Tanzania tourism suffers after election killings
-
Yo-de-lay-UNESCO? Swiss hope for yodel heritage listing
-
Weatherald fires up as Australia race to 130-1 in second Ashes Test
-
Georgia's street dogs stir affection, fear, national debate
-
Survivors pick up pieces in flood-hit Indonesia as more rain predicted
-
Gibbs runs for three TDs as Lions down Cowboys to boost NFL playoff bid
-
Pandas and ping-pong: Macron ending China visit on lighter note
-
TikTok to comply with 'upsetting' Australian under-16 ban
-
Hope's resistance keeps West Indies alive in New Zealand Test
-
Pentagon endorses Australia submarine pact
-
India rolls out red carpet for Russia's Putin
-
Softbank's Son says super AI could make humans like fish, win Nobel Prize
-
LeBron scoring streak ends as Hachimura, Reaves lift Lakers
-
England all out for 334 in second Ashes Test
-
Hong Kong university axes student union after calls for fire justice
-
'Annoying' Raphinha pulling Barca towards their best
-
Prolific Kane and Undav face off as Bayern head to Stuttgart
-
Napoli's title defence continues with visit of rivals Juventus
-
Nice host Angers with storm clouds gathering over the Riviera
-
OpenAI strikes deal on US$4.6 bn AI centre in Australia
-
Rains hamper Sri Lanka cleanup after deadly floods
-
In India's mining belt, women spark hope with solar lamps
-
After 15 years, Dutch anti-blackface group declares victory
-
Eyes of football world fixed on 2026 World Cup draw with Trump presiding
-
West Indies on the ropes in record run chase against New Zealand
-
'Only a miracle can end this nightmare': Eritreans fear new Ethiopia war
-
Unchecked mining waste taints DR Congo communities
-
McIntosh swims second-fastest 400m free ever in US Open triumph
-
Asian markets mixed ahead of US data, expected Fed rate cut
-
French almond makers revive traditions to counter US dominance
Trump announces Pfizer deal he says will lower certain drug prices
The Trump administration on Tuesday announced a deal granting Pfizer a three-year reprieve on planned tariffs as the pharmaceutical giant vowed to voluntarily lower the prices of unspecified drugs for US purchase.
President Donald Trump, flanked by top health officials, was scant on details regarding what or how many drugs were included in the agreement, the announcement of which came as Washington faced a looming government shutdown.
Under the deal Pfizer is to charge "Most Favored Nation" pricing -- matching the lowest price offered in other wealthy nations -- to Medicaid, the US health insurance program for low-income Americans.
The White House also said it would unveil a website -- called TrumpRx -- that would allow consumers to directly purchase some medications from manufacturers at discounted rates.
Like Trump, Pfizer CEO Albert Bourla heralded the deal as a great achievement, although a statement from the company was equally vague on specifics.
The company did say a "large majority" of "primary care treatments and some select specialty brands" could be offered at savings from 50 percent to 85 percent.
"We now have the certainty and stability we need on two critical fronts, tariffs and pricing, that have suppressed the industry's valuations to historic lows," said Bourla.
Part of the deal included Pfizer agreeing to "invest $70 billion to reshore domestic manufacturing facilities" to the United States.
- Wider impact unclear -
Trump's initiative revives drug-pricing efforts from his first term. The president has taken steps since returning to the White House to pressure pharmaceutical companies into voluntarily lowering their prices.
In July the US leader sent letters to leading pharmaceutical companies demanding they lower drug prices.
Democrats have long indicated that they, too, would like to lower drug prices.
In a report released Monday, independent Senator Bernie Sanders said that Trump's efforts on the issue had "made headlines" but had done "little beyond that."
The member of the Senate's health committee said in his report that since Trump sent the letters over the summer, the prices of 87 drugs actually increased.
Drug costs for consumers in the United States can depend on several variables, notably insurance coverage.
Many people receive insurance through an employer, the health insurance market or government programs including Medicare, which is for seniors, and the safety net Medicaid.
It is not clear how Tuesday's deal will impact drug pricing in the commercial insurance market.
The announcement comes as drugmakers gird for a 100-percent tariff Trump said he would impose on branded pharmaceutical products entering the country from October 1 -- unless companies were building manufacturing plants in the United States.
But details surrounding the rollout remain unclear.
Since returning to the presidency in January, Trump has imposed sector-specific tariffs on imports like steel, aluminum and autos, while launching investigations into other areas like pharmaceuticals that could lead to new levies.
Asked Tuesday about the timeline for fresh tariffs, Commerce Secretary Howard Lutnick said the Trump administration plans to allow negotiations with companies to play out.
P.Hernandez--AT